

Fig 1. Docetaxel PK profile in representative patient with normal liver function (\square) and patient with elevated hepatic enzymes (\blacksquare). Lines denote model predictions after Bayesian estimation.

T06290-58969860




Fig 2. Docetaxel population PK profile in a subset of 254 patients.




Fig 3. Model-predicted probability of febrile neutropenia as a function of CLf for a patient with median AAG. Reference vertical lines denote normal CL (CLf = 1) and 50% reduced CL (CLf = 2).

DOCETAXEL - LUNG

Survival




Figure 4: survival curves in NSCLC patients with low (≤ 1.11 g/L, —), intermediate (1.12 to 1.84 g/L, ----) and high (≥ 1.85 , -•-•-) baseline AAG (/censored observation)